Verily, Alphabet’s independent subsidiary dedicated to the study of life sciences, has received a massive $800 million investment from Temasek. A major part of this funding will be received in the coming few days while the remaining will come in the second half of this year.
In case you are unaware of the fact, Verily was previously Google Life Sciences.
Temasek is a Singapore based investment company which funds a variety of industries and Global Offices all around the world. As previously stated in a press release, the firm lays emphasis on companies tackling long term trends, and Verily’s commendable attempts of highlighting issues such as declining vision and Parkinson’s disease has made it a perfect choice for the investment firm.
Verily is also working on disease detection, along with attempting to rejuvenate the Star Trek’s Tricorder, which would thoroughly examine living beings for any disease. The Stat News reports however, state that the firm hasn’t received anticipated success in this area.
However, Verily is also working on a project of establishing a healthy baseline down the genetic level for the humans. They are also working on wristbands which would monitor the patients continuously and act as a prescription device. Some other projects include advanced surgical robots and robotic bugs which would prevent transmission of diseases.
The investment will gain Temasek a small stake in Verily, and now they may also nominate their own board member for the Google subsidiary. Andrew Conrad, CEO Verily, announced in a press release that Temasek’s investments will help them strategically, as they target expanding their business in Asia and beyond U.S.
The investment is sure to bring more of commercialization in Verily, and it will help make the business more productive — leading to more revenues for Google. The investments will also help fuel research in a very important field and could help humans live better in the future.
